GLP1 FAQ

Microdosing is a modern wellness approach that uses smaller, consistent doses of compounded GLP-1/GIP formulations — along with supportive nutrients — designed to promote daily balance and overall wellness. Unlike standard GLP-1 therapy (which targets diabetes or weight management at therapeutic doses), microdosing uses lower, subtherapeutic doses focused on metabolic balance, steady energy, mental clarity, and appetite awareness. These formulations are not FDA-approved. Always consult a licensed healthcare provider before starting any program.

Standard GLP-1 therapy uses therapeutic doses designed to treat diabetes or drive significant weight loss. Microdosing uses lower, subtherapeutic doses with a primary focus on daily wellness, longevity, and metabolic balance — not aggressive weight reduction. The approach is gentler, typically producing a smaller side-effect profile, and is aimed at people seeking long-term wellness support rather than rapid weight change.

Yes. Compounded GLP-1/GIP formulations require a prescription from a licensed physician in the United States. All legitimate providers require a telemedicine consultation and physician review before dispensing. Be cautious of any source offering these compounds without a physician consultation.

No. These compounded GLP-1/GIP formulations are not FDA-approved. They are prepared by licensed compounding pharmacies under physician supervision but have not undergone the full FDA drug approval process. It is essential to always consult a licensed healthcare provider before starting any microdosing program to ensure it is appropriate for your individual health situation.

Microdose GLP-1/GIP can be administered as weekly subcutaneous injections or daily oral tablets (ODT/lozenges). Injections are typically self-administered in the abdomen, thigh, or upper arm. Oral formats dissolve under the tongue for sublingual absorption. Your prescribing physician will recommend the best format based on your goals and health profile.

GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are both incretin hormones involved in metabolic regulation. GLP-1 primarily supports appetite regulation and blood sugar balance; GIP works synergistically to enhance metabolic effects. Combined GLP-1/GIP formulations may offer broader metabolic wellness support. Your provider will recommend the appropriate formulation for your goals.

Microdosing may support: energy and physical vitality, metabolic health and blood sugar balance, mental clarity and focus, sleep quality, muscle maintenance and recovery, and inflammation reduction. These formulations are designed for daily wellness goals — not as a primary weight loss treatment. Results vary by individual; consult a licensed healthcare provider to determine if microdosing is right for you.

Yes — licensed telehealth providers offer microdose GLP-1/GIP programs fully online. The process is entirely remote: complete a health questionnaire, receive a physician review, and if approved, your compounded medication ships directly to your home. All providers listed on this site require physician oversight and offer home delivery.

Online microdose GLP-1/GIP programs typically range from approximately $99–$225 per month depending on the provider and format. Most programs include physician consultation, compounded medication, and shipping. Compare providers on this site for current, up-to-date pricing.

Most insurance plans do not cover compounded GLP-1/GIP formulations prescribed for wellness or longevity goals. Some coverage may be available for diabetes management in certain cases. Contact your insurer directly and consult a licensed provider about your specific options.

Because microdosing uses lower, subtherapeutic doses, side effects are generally milder than standard GLP-1 therapy. Potential effects may include mild nausea, injection site reactions, appetite changes, or digestive sensitivity — particularly during the initial adjustment period. Report any persistent or concerning symptoms to your prescribing physician.

When supervised by a licensed physician and using properly compounded medications from accredited pharmacies, microdosing programs have a generally favorable safety profile due to the lower doses used. However, these formulations are not FDA-approved, and long-term safety data is still accumulating. Individual responses vary. Always work with a licensed healthcare provider to determine if microdosing is appropriate for you.

Microdose GLP-1/GIP may not be appropriate for individuals with active malignancy, personal or family history of medullary thyroid carcinoma, pancreatitis, or pregnancy. Complete medical history disclosure to your prescribing physician is essential. Thorough intake evaluation is required before any legitimate provider will dispense these formulations.

Most users report improvements in energy and sleep quality within 2–4 weeks. Mental clarity improvements often follow within 4–6 weeks. Metabolic balance changes — including improved appetite awareness and steadier blood sugar — are typically more noticeable after 2–3 months of consistent use. Individual results vary significantly based on lifestyle, diet, and health status.

Standard weight-loss doses are significantly higher therapeutic doses designed to produce meaningful appetite suppression and body weight reduction. Microdosing uses subtherapeutic doses aimed at metabolic balance, energy, and daily wellness — without the aggressive appetite suppression of full therapeutic dosing. Microdosing is not designed as a primary weight loss treatment; it is a wellness and longevity tool used at lower dose ranges.